Quantification of ER/PR expression in ovarian low-grade serous carcinoma (Q45817225)

16 December 2017

title

Quantification of ER/PR expression in ovarian low-grade serous carcinoma (English)

1 reference

16 December 2017

low-grade serous carcinoma

main subject

0 references

author

Martin Köbel

9

1 reference

16 December 2017

author name string

Jorge Escobar

1

1 reference

16 December 2017

Alexander C Klimowicz

2

1 reference

16 December 2017

Michelle Dean

3

1 reference

16 December 2017

Pamela Chu

4

1 reference

16 December 2017

Jill G Nation

5

1 reference

16 December 2017

Gregg S Nelson

6

1 reference

16 December 2017

Prafull Ghatage

7

1 reference

16 December 2017

Steve E Kalloger

8

1 reference

16 December 2017

language of work or name

English

0 references

publication date

24 October 2012

1 reference

16 December 2017

published in

Gynecologic Oncology

1 reference

16 December 2017

volume

128

1 reference

16 December 2017

issue

2

1 reference

16 December 2017

page(s)

371-376

1 reference

16 December 2017

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Low-grade serous primary peritoneal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Diverse tumorigenic pathways in ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Ovarian low-grade serous carcinoma: a comprehensive update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Hormonal therapies and gynaecological cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Recurrent psammocarcinoma of the peritoneum with complete response to tamoxifen therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Architectural patterns of ovarian/pelvic high-grade serous carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Automated subcellular localization and quantification of protein expression in tissue microarrays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Grading ovarian serous carcinoma using a two-tier system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Estrogen receptor expression is a common feature of ovarian borderline tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Calculator for ovarian carcinoma subtype prediction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immuno

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Quantitative, fluorescence-based in-situ assessment of protein expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.10.013

10.1016/J.YGYNO.2012.10.013

7 January 2021

Identifiers

DOI

1 reference

16 December 2017

release_zbqragtjlnhihctzpln7f23wiu

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zbqragtjlnhihctzpln7f23wiu

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

23103384

1 reference

16 December 2017